



Author(s):
Question: Immunonutrition compared to standard formula in pancreatic surgery
Setting:
Bibliography: 1,2

Certainty assessment							N _e of patients		Effect		Certainty	Importance
N _e of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	immunonutrition	standard formula	Relative (95% CI)	Absolute (95% CI)		
Tagaki 2020, postsurgical complications (assessed with: riesgo relativo)												
5	randomised trials	serious	not serious	not serious	not serious	none	46/107 (43.0%)	98/175 (56.0%)	RR 0.74 (0.58 to 0.94)	146 fewer per 1000 (from 235 fewer to 34 fewer)	⊕⊕⊕⊕ Moderate	IMPORTANT
Tagaki 2020, major complications (assessed with: RR)												
5	randomised trials	serious ^a	not serious	not serious	not serious	none	24/107 (22.4%)	49/175 (28.0%)	RR 0.68 (0.41 to 1.12)	90 fewer per 1000 (from 165 fewer to 34 more)	⊕⊕⊕⊕ Moderate	IMPORTANT
Tagaki 2020, mortality (assessed with: RR)												
5	randomised trials	serious ^a	not serious	not serious	not serious	none	2/127 (1.6%)	5/185 (2.7%)	RR 0.79 (0.16 to 3.99)	6 fewer per 1000 (from 23 fewer to 81 more)	⊕⊕⊕⊕ Moderate	IMPORTANT
Tagaki 2020, infectious complications (assessed with: RR)												
5	randomised trials	serious	not serious	not serious	not serious	none	31/144 (21.5%)	60/205 (29.3%)	RR 0.60 (0.42 to 0.84)	117 fewer per 1000 (from 170 fewer to 47 fewer)	⊕⊕⊕⊕ Moderate	IMPORTANT
Yang 2020, general complications (assessed with: RR)												
6	randomised trials	not serious	not serious	not serious	not serious	none	35/104 (33.7%)	46/108 (42.6%)	RR 0.79 (0.50 to 0.12)	89 fewer per 1000 (from 375 fewer to 213 fewer)	⊕⊕⊕⊕ High	IMPORTANT
Yang 2020, infectious complications												
6	randomised trials	not serious	not serious	not serious	not serious	none	16/129 (12.4%)	32/133 (24.1%)	RR 0.50 (0.30 to 0.84)	120 fewer per 1000 (from 168 fewer to 38 fewer)	⊕⊕⊕⊕ High	IMPORTANT
Yang 2020 mortality (assessed with: RR)												
6	randomised trials	not serious	not serious	not serious	not serious	none	3/148 (2.0%)	2/149 (1.3%)	RR 1.35 (0.27 to 6.88)	5 more per 1000 (from 10 fewer to 79 more)	⊕⊕⊕⊕ High	IMPORTANT
Yang 2020 long of stay												
6	randomised trials	not serious	not serious	not serious	not serious	none	LOS MD = −2.03; 95% CI = −3.78, −0.45; p = 0.01)			⊕⊕⊕⊕ High	IMPORTANT	
Guan 2019 general complications (assessed with: RR) ³												
4	randomised trials	serious	not serious	not serious	not serious	none	51/129 (39.5%)	65/133 (48.9%)	RR 0.81 (0.62 to 1.05)	93 fewer per 1000 (from 186 fewer to 24 more)	⊕⊕⊕⊕ Moderate	IMPORTANT
Guan 2019, infectious complications												

4	randomised trials	serious	not serious	not serious	not serious	none	21/146 (14.4%)	52/153 (34.0%)	RR 0.58 (0.37 to 0.92)	143 fewer per 1000 (from 214 fewer to 27 fewer)	 Moderate	IMPORTANT
---	-------------------	---------	-------------	-------------	-------------	------	----------------	----------------	----------------------------------	---	---	-----------

Guan 2019, mortality

4	randomised trials	serious	not serious	not serious	not serious	none	3/129 (2.3%)	1/133 (0.8%)	RR 2.43 (0.37 to 16.10)	11 more per 1000 (from 5 fewer to 114 more)	 Moderate	IMPORTANT
---	-------------------	---------	-------------	-------------	-------------	------	--------------	--------------	-----------------------------------	---	---	-----------

CI: confidence interval; RR: risk ratio

Explanations

a. Risk of vias

References

1.Takagi, . . Langenbecks Arch Surg (2020) 405:585–593;
2.Yang F, et al.. Immunonutrition in Patients with Pancreatic Cancer Undergoing Surgical Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients ; 2020, .
3.Guan H, et al. Effects of Enteral Immunonutrition in Patients Undergoing Pancreaticoduodenectomy: A Meta-Analysis of Randomized Controlled Trials. Ann Nutr Metab 2019;74:53–61;